Adeodata Kekitiinwa1, Victor Musiime2,3, Margaret J Thomason4, Grace Mirembe2, Marc Lallemant5, Sarah Nakalanzi1, David Baptiste4, A Sarah Walker4, Diana M Gibb4, Ali Judd4. 1. Department of Pediatrics and Adolescent Health, Baylor College of Medicine Children's Foundation Uganda, Paediatric Infectious Diseases Clinic, Mulago Hospital Kampala, Kampala, Uganda. 2. Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda. 3. Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda. 4. Medical Research Council Clinical Trials Unit, University College London, London, UK. 5. HCV and Paediatric HIV Program, Drugs for Neglected Diseases initiative, Geneva, Switzerland.
Abstract
BACKGROUND:Lopinavir/ritonavir 'pellets' were recently tentatively approved for licensing. We describe their acceptability for infants and children up to 48 weeks. METHODS: CHAPAS-2 was a randomized, two-period crossover trial comparing syrup and pellets in HIV-infected infants (n=19, group A, aged 3-<12 months) and children (n=26, group B, 1-<4 years) and tablets and pellets in older children (n=32, group C, 4-<13 years) from two clinics ('JCRC', 'PIDC') in Uganda. At week 8, all groups chose which formulation to continue. Acceptability data were collected at weeks 0, 4, 8, 12 and 48. RESULTS: For groups A and B overall, the proportion preferring pellets increased between week 0 and week 12 and decreased at week 48 (group A 37%, 72%, 44%; group B 12%, 64% and 36%, respectively), although there were marked differences between clinics. For group C, pellets were progressively less preferred to tablets over time: 41%, 19% and 13% at weeks 0, 12 and 48, respectively. During follow-up unpleasant taste was similarly reported among young children taking pellets and syrups (37%/43% group A; 29%/26% group B), whereas among older children, pellets tasted worse than tablets (40%/2%). No participants reported problems with storage/transportation for pellets (0%/0%) unlike syrups (23%/13%). CONCLUSIONS: For children <4 years, pellets were more acceptable at week 12 but not week 48. Clinic differences could reflect bias among health-care workers for different formulations. Pellets taste similar to syrup, are easier to store and transport than syrup and represent an alternative formulation for young children unable to swallow tablets; improvements in taste and support for health-care workers may help sustain acceptability.
RCT Entities:
BACKGROUND:Lopinavir/ritonavir 'pellets' were recently tentatively approved for licensing. We describe their acceptability for infants and children up to 48 weeks. METHODS: CHAPAS-2 was a randomized, two-period crossover trial comparing syrup and pellets in HIV-infectedinfants (n=19, group A, aged 3-<12 months) and children (n=26, group B, 1-<4 years) and tablets and pellets in older children (n=32, group C, 4-<13 years) from two clinics ('JCRC', 'PIDC') in Uganda. At week 8, all groups chose which formulation to continue. Acceptability data were collected at weeks 0, 4, 8, 12 and 48. RESULTS: For groups A and B overall, the proportion preferring pellets increased between week 0 and week 12 and decreased at week 48 (group A 37%, 72%, 44%; group B 12%, 64% and 36%, respectively), although there were marked differences between clinics. For group C, pellets were progressively less preferred to tablets over time: 41%, 19% and 13% at weeks 0, 12 and 48, respectively. During follow-up unpleasant taste was similarly reported among young children taking pellets and syrups (37%/43% group A; 29%/26% group B), whereas among older children, pellets tasted worse than tablets (40%/2%). No participants reported problems with storage/transportation for pellets (0%/0%) unlike syrups (23%/13%). CONCLUSIONS: For children <4 years, pellets were more acceptable at week 12 but not week 48. Clinic differences could reflect bias among health-care workers for different formulations. Pellets taste similar to syrup, are easier to store and transport than syrup and represent an alternative formulation for young children unable to swallow tablets; improvements in taste and support for health-care workers may help sustain acceptability.
Authors: Brookie M Best; Edmund V Capparelli; Huy Diep; Steven S Rossi; Michael J Farrell; Elaine Williams; Grace Lee; John N van den Anker; Natella Rakhmanina Journal: J Acquir Immune Defic Syndr Date: 2011-12-01 Impact factor: 3.731
Authors: Jincheng Yang; Mina Nikanjam; Brookie M Best; Jorge Pinto; Ellen G Chadwick; Eric S Daar; Peter L Havens; Natella Rakhmanina; Edmund V Capparelli Journal: J Clin Pharmacol Date: 2018-09-25 Impact factor: 3.126
Authors: Christine Y Malati; Rachel Golin; Lisa O'Brien; Nandita Sugandhi; Meena Srivastava; Chris Larson; Benjamin R Phelps Journal: J Int AIDS Soc Date: 2019-04 Impact factor: 5.396
Authors: Grace Li; Charlotte Jackson; Julia Bielicki; Sally Ellis; Yingfen Hsia; Mike Sharland Journal: Bull World Health Organ Date: 2020-05-08 Impact factor: 9.408